OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP)
Friday’s Closing PPS: $0.21
I know it’s Super Bowl Sunday and you’re probably getting prepared for tonight so I’m going to keep this intro short and just jump right into my full report on my latest cancer fighting trade alert (OBMP)!
**OBMP** is a REAL Biopharmaceutical trade opportunity with a proprietary vaccine technology to help cancer patients!
OBMP is my very first trade alert to have an actual tested and proven safe cancer fighting vaccine!
Take a look at a real testimonial from one of OBMP’s real patients:
“I am confident that the vaccine Dr. Elliott has been working on for nearly two decades is the reason that I am still alive and well and able to live a fulfilling life. Since receiving it, I have urged other men to consider this treatment which was successful for me.”
OBMP is currently poised for another potential BREAKOUT. Take a look at the chart… On 1/09/17 shares of OBMP went from a low of $0.10 to a high of $0.27 on 1/23/17! That’s a REAL MOVE of +170pct!
As you can clearly see from the chart; OBMP has been known to make traders substantial profits in the short-term.
How big is the Biopharmaceutical industry?
According to a new market report published by Persistence Market Research “Global Market Study on Biopharmaceuticals: Asia to Witness Highest Growth by 2020”, the global biopharmaceuticals market was valued at US$ 162 Bn in 2014 and is expected to grow at a CAGR of 9.4% from 2014 to 2020, to reach an estimated value of US$ 278 Bn by 2020.
OBMP is a super hot cancer fighting biopharma trade opportunity that is loaded with potential juicy profits right now.
Remember to always do your own research and due diligence and that I’m not a licensed financial advisor.
Back in June 2016 when OBMP ran from a low of $0.10 to a high of $0.35…
… Traders witnessed real potential gains of up to +249pct!
With a market-cap of just $12M and a relatively low float under 10M shares; OBMP could once again provide traders profits from its current undervalued price per share.
The 9-day RSI is currently at a very bullish 60 suggesting its current upwards trend will continue to strengthen.
Barchart has given (OBMP) a 56pct OVERALL GREEN Rating + a 60pct GREEN Rating for the Short-Term!
Additional Short-Term Indicators:
7 Day Average Directional Indicator: GREEN
20 Day Moving Average Vs Price: GREEN
20 – 50 Day MACD Oscillator: GREEN
Exponential Moving Average (EMA) Analysis: VERY BULLISH
Moving Average Convergence Divergence (MACD) Analysis: VERY BULLISH
Fibonacci Analysis: BULLISH
OBMP Company Profile
OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology that is designed to stimulate the immune system to selectively attack cancer cells without harm to the patient. The vaccine technology has been proven safe through use in more than 300 patients without a single serious adverse event.
Our lead product, ProscaVax™ for prostate cancer, is near conclusion of a Phase 1 trial funded by the Department of Defense Navy Cancer Vaccine Program. Based upon data showing ProscaVax is non-toxic and can lower PSA levels, we are moving ProscaVax into a Phase 2 trial for prostate cancer patients in the “Active Surveillance” category, an early stage of disease for which there are currently no treatments without significant morbidities. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs, including paclitaxel (Abraxane). OncBioMune is headquartered in Baton Rouge, LA.
Dr. Jonathan Head, Ph.D.
CHIEF EXECUTIVE OFFICER, CHAIRMAN
Dr. Head has been instrumental in the development of our new chemotherapy and immunotherapy programs. Dr. Head and Dr. Elliott are the co-developers and patent holders of one of the first patented autologous breast cancer vaccines in the United States. His major goal is to implement translational research – the movement of laboratory-developed technologies into the clinical setting. This is the taking of new therapies from cell culture to an accepted therapy for cancer patients.
As a tumor cell biologist, Dr. Head’s specialties include:
Cell culture research
Animal research
Human clinical research
Innovative chemotherapies
Immunotherapy/cancer vaccines
Oncogene and antisense research
Tumor markers
Dr. Head is an Adjunct Associate Professor of Biochemistry at Tulane University School of Medicine, an Adjunct Professor of Physical and Biological Sciences at Delta State University and an Adjunct Associate Professor at Louisiana State University School of Veterinary Medicine. He is an active member of the American Association for Cancer Research and the American Society of Clinical Oncology. Although patients rarely meet Dr. Head, the new treatments we offer are the result of his and Dr. Elliott’s work.
ProscaVax – A Novel Prostate Cancer Vaccine
The Company has developed a therapeutic cancer vaccine for prostate cancer patients using similar techniques developed for breast cancer patients. It is tested and laboratory proven and could become the standard of care for prostate cancer treatment.
The Company incorporates scientifically proven and clinically validated treatments for cancer. We utilize patented technology developed and or acquired by OncBioMune. The intellectual property consists of multiple technologies combined with laboratory and clinical procedures that provide new insight into the treatment of cancer. The Company’s proprietary technology provides the necessary tools for the successful treatment of patient’s with a therapeutic vaccine. It is marketable and would be very profitable upon FDA approval.
The Company has data from a phase 1/2 clinical trial of their therapeutic prostate cancer vaccine. Patients with prostate cancer confirmed by biopsy and with an elevated PSA received the vaccine. We enrolled 12 patients in this study. All patients received their initial course of six vaccinations containing prostate specific antigen and biological adjuvant. Serum PSA concentrations were determined before initiating vaccination and 3-4 weeks after the 6th vaccination. Two-thirds of the prostate cancer patients’ PSAs decreased after vaccination. During the trial the prostate cancer patients received no other concurrent therapy (surgery, hormone, radiation, radioactive seeds, chemotherapy), and have additionally received three further vaccinations alternated with low dose IL-2 for the 6 months following the initial vaccinations. The Company developed the protocol for the vaccination of prostate cancer patients using techniques developed for vaccination of breast cancer patients. We are currently in a Phase 1 clinical trial at UCSD Medical School under an IND from the FDA with funding from the US Navy Cancer Vaccine Program. If proven effective clinically, it could become the standard of care for prostate cancer.
Latest Clinical Data from OncBioMune Supports Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for Upcoming Phase 2 Clinical Trials
BATON ROUGE, LA–(Marketwired – January 26, 2017) – OncBioMune Pharmaceuticals, Inc. (OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today provides the latest clinical data of ProscaVax, the Company’s novel therapeutic prostate cancer vaccine.
In the ongoing Phase 1 clinical trial, ProscaVax is being evaluated for safety and efficacy in prostate specific antigen (PSA) recurrent prostate cancer in hormone-naïve and hormone-independent patients. Per protocol, 20 patients are expected to be enrolled in the 1a portion of the study, with therapy consisting of six ProscaVax induction vaccinations at a single dose. To date, 16 prostate cancer patients have enrolled in the trial.
The trial is being hosted at the University of California San Diego Moores Cancer Center and Veterans Hospital in La Jolla, California under an IND from the U.S. Food and Drug Administration with funding from the U.S. Navy Cancer Vaccine Program.
Additional preliminary data from the trial shows ProscaVax to provide a meaningful clinical benefit to prostate cancer patients. These data include:
15 of 20 patients* in the Phase 1a portion of the trial have received at least one vaccine injection and 14 patients have received all 6 vaccines.
None of the 15 patients who have had at least one vaccine have had a DLAE.
None of the 14 patients who have received all 6 vaccines in the Phase 1a have had a DLAE.
9 of the 14 patients that have received 6 vaccines have had increased PSA doubling time, suggesting ProscaVax is slowing tumor growth.
11 of the 13 patients** that have received 6 vaccines have had increased immune responses to PSA as determined with a Lymphocyte Blastogenesis Assay by 31 weeks post-vaccine.
3 of the 14 patients that have received all 6 vaccines have experienced disease progression (one radiological, two PSA)
Data from this trial combined with previous in-house studies have established a strong safety profile for ProscaVax, while providing evidence of a therapeutic benefit that warrants larger clinical trials. OncBioMune is preparing to enter a Phase 2/3 trial in Mexico through a Joint Venture with its acquisition target and Mexican partner Vitel Laboratorios S.A. de C.V. Inclusion criteria for the Phase 2/3 trial will be similar to the ongoing Phase 1 trial. A second Phase 2 trial is planned in the United States at a prominent Northeast university cancer center evaluating ProscaVax at disease presentation in early-stage prostate cancer patients in the “active surveillance” population.
“We’re very excited by the updated data that once again supports our thesis that ProscaVax can provide a meaningful benefit to prostate cancer patients without the horrible side effects well known to accompany today’s approved therapies,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “We greatly look forward to our upcoming Phase 2 studies where we will be adding six ProscaVax booster injections, which we believe has the potential to further increase efficacy for both early and late-stage prostate cancer patients.”
Start your research and due diligence on OBMP right now.
P.S. – Take a look at some of my latest and biggest verified winning trade ideas below:
My Top Recent Trade Alerts
1/10/17 – (KDRH) Ran From .0169 to .076 = +349pct
1/19/17 – (ASTI) Ran From .0023 to .0078 = +239pct
1/27/17 – (TLPC) Ran From .01765 to .20 = +1033pct
These Percentage Runs Are Based From The Open To HOD
Make sure to always do your own research and due diligence on any day and swing trade alert I bring to your attention. I am not a licensed financial advisor.
Also always remember that every single alert I send is very volatile and risky. Any one of them could turn into a big loser. In my personal opinion, no matter how much potential any company has, 99pct of the time all that matters is how it trades. If a company doesn’t trade well, nothing else matters. Don’t believe the hype. Be sure to use a tight stop, book gains quickly on these volatile trades, never let any one trade move too far against you, watch out for gaps, make sure the company is trading in a healthy way before you enter, and monitor it closely to make sure momentum is positive. It’s always safest to book gains quickly, even on alerts with long-term potential. (Amateur biased unlicensed opinions)
Pursuant to an agreement between SmallCapFirm and Awareness Consulting Network, LLC (a non affiliated 3rd party), SmallCapFirm has been hired for a period beginning on 2/05/17 and ending on 2/06/17 to publicly disseminate information about (OBMP) via Website, Email and SMS. We have been paid eleven thousand USD via bank wire transfer. We own zero shares of (OBMP).
SmallCapFirm’s full disclaimer is to be read and fully understood before using SmallCapFirm’s website, or joining SmallCapFirm’s email or text list. By viewing SmallCapFirm’s website and/or reading SmallCapFirm’s email or text newsletter you are agreeing to SmallCapFirm’s full disclaimer which can be read at:
